Skip to main content
. Author manuscript; available in PMC: 2021 Jan 5.
Published in final edited form as: Int J Pharm. 2019 Nov 23;573:118894. doi: 10.1016/j.ijpharm.2019.118894

Figure 4.

Figure 4.

MP38 cell viability after treated with HIF-1α siRNA-loaded complexes (A) and scramble siRNA-loaded complexes (B) for 48 and 72 hr under hypoxia conditions. Chitosan (Chi) solutions with the same concentrations as that used in the complexes with N/P ratios with 20/1 (low conc.) and 40/1 (high conc.), hyaluronic acid (HA) solutions with the same concentrations as that used in the ternary complexes with C/N/P ratios of 10/40/1 (low conc.) and 40/40/1 (high conc.), and a commercial agent DharmaFECT 1 (DF) were studied as controls.